Navigation Links
Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results
Date:5/3/2011

BEIJING, May 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2011 before market on Friday, May 13, 2011.  The Company will host a conference call on Friday, May 13, 2011 at 8:00 a.m. EDT (March 13, 2011 at 8:00 pm China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international).  A replay of the call will be available from 11 a.m. EDT on May 13, 2011 to May 27, 2011 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and reference the replay pin number 371847.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning May 13, 2011 and the replay will remain available for 30 days.

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel:  +86-10-8279-9871/9659Fax:  +86-10-6296-6910Email: ir@sinovac.com Investors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel:  +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.com MediaJason RandoThe Ruth GroupTel:  +1-646-536-7025Email:  jrando@theruthgroup.com
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
2. Sinovac Participates in Two Investor Conferences in November
3. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
4. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
5. Sinovac Reports Unaudited First Quarter 2010 Financial Results
6. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
7. Sinovac Announces Upsizing and Pricing of Common Share Offering
8. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
9. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
10. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
11. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... SAN DIEGO , Jan. 11, 2017 /PRNewswire/ ... first-in-class antibody product candidates focused on unmet medical ... Dominic Piscitelli as chief financial officer.  ... AnaptysBio,s finance strategy, as well as overseeing the ... "We are pleased to welcome Dominic to ...
(Date:1/11/2017)... MINNEAPOLIS , Jan. 11, 2017 ... Consortium (CBQC) today announced that it has partnered ... products for life science research and diagnostics. The ... a soluble form of receptor for advanced ... biomarker to support subject selection for clinical trials ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... enterprise-quality business communication technologies, with on premise functionality, from the cloud. MacDonald-Miller Facility ... partnership to leverage their existing Microsoft Office 365 E5 licensing to its maximum ...
(Date:1/10/2017)... ... January 10, 2017 , ... Clinical Supplies ... acquired B&C Group (“B&C”) based in Brussels, Belgium. CSM and B&C have had ... B&C and their management team into the CSM family. The addition of the ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):